References
- Petrosillo N, Viceconte G, Ergonul O, et al. COVID-19, SARS and MERS: are they closely related? Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect. 2020;26(6):729–734.
- Vaira LA, Deiana G, Fois AG, et al. Objective evaluation of anosmia and ageusia in COVID-19 patients: single-center experience on 72 cases. Head Neck. 2020;42(6):1252–1258.
- Vaira LA, Hopkins C, Salzano G, et al. Olfactory and gustatory function impairment in COVID-19 patients: Italian objective multicenter-study. Head Neck. 2020;42(7):1560–1569.
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
- Pardo J, Shukla AM, Chamarthi G, et al. The journey of remdesivir: from Ebola to COVID-19. DIC. 2020;9:1–4.
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - preliminary report. Reply. N Engl J Med. 2020;383(19):1813–1826.
- U.S Food and Drug Administration. FDA approves first treatment for COVID-19. 2020. [cited 2020 Sep 2]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19.
- Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100(2):446–454.
- Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with favipiravir for ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016;13(3):e1001967–e67.
- Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020;6(10):1192–1198.
- Chen C, Zhang Y, Huang J, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020. DOI:10.1101/2020.03.17.20037432.
- Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? J Virus Eradic. 2020;6(2):45–51.
- Saudi Arabia Ministry of Health (MOH). Saudi MoH Protocol for Patients Suspected of/Confirmed with COVID-19. [cited 2020 Sep 2]. Available from: https://www.moh.gov.sa/Ministry/MediaCenter/Publications/Documents/MOH-therapeutic-protocol-for-COVID-19.pdf.
- Equator Network. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. 2020.
- Vassar M, Holzmann M. The retrospective chart review: important methodological considerations. J Educ Eval Health Prof. 2013;10:12.
- Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inf. 2019;95:103208–103208.
- Saudi Arabia Ministry of Health (MOH). Coronavirus Disease COVID-19 Guidelines, v1.3. [cited 2020 Sep 2]. Available from: https://www.moh.gov.sa/Ministry/MediaCenter/Publications/Documents/Coronavirus-Disease-2019-Guidelines-v1.2.pdf.
- World Health Organization. Criteria for releasing COVID-19 patients from isolation. [cited 2020 Mar 22]. Available from: https://www.who.int/news-room/commentaries/detail/criteria-for-releasing-covid-19-patients-from-isolation.
- U.S Department of Health and Human Services & National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. [cited 2020 Sep 2]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
- Therneau TM. A package for survival analysis in R. 2020. [cited 2020 Aug 1]. Available from: https://CRAN.R-project.org/package=survival.
- Scheike TH, Zhang M-J. Analyzing competing risk data using the R timereg package. J Stat Soft. 2011;38(2):i02.
- Sterne JAC, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393.
- van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. J Stat Soft. 2011;1(3):1–67.
- Deeks JJ, Higgins JPT, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions. London: Cochrane; 2019. p. 241–284.
- Pishgar F, Greifer N, Leyrat C, et al. MatchThem: matching and weighting after multiple imputation. arXiv e-Prints 2020:arXiv:2009.11772.
- Mitra R, Reiter JP. A comparison of two methods of estimating propensity scores after multiple imputation. Stat Methods Med Res. 2016;25(1):188–204.
- Lumley T. Analysis of complex survey samples. J Stat Soft. 2004;9(8):1–19.
- Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for COVID-19 - interim WHO Solidarity trial results. N Engl J Med. 2021;384(6):497–511.
- U.S Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibodies for treatment of COVID-19. [cited 2020 Aug 1]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19.
- Wooding DJ, Bach H. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Clin Microbiol Infect. 2020;26(10):1436–1446.
- Parr JB. Time to reassess Tocilizumab’s role in COVID-19 pneumonia. JAMA Intern Med. 2021;181(1):12.
- Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384(8):693–704.
- Rafi MO, Bhattacharje G, Al-Khafaji K, et al. Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19. J Biomol Struct Dyn. 2020;30:1–20.
- National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. [cited 2020 Aug 1]. Available from: https://www.covid19treatmentguidelines.nih.gov.
- Brigham and women's. Brigham and women's hospital inpatient COVID 19 infectious diseases treatment guidelines. [cited 2020 Aug 1]. Available from: https://covidprotocols.org/en/chapters/treatments/.
- Wang Y, Chen L. Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment. Eur J Pharmacol. 2020;889:173634–173634.
- Rattanaumpawan P, Jirajariyavej S, Lerdlamyong K, et al. Real-world experience with favipiravir for treatment of COVID-19 in Thailand: results from a multi-center observational study. medRxiv. 2020;13(5):880–885.
- Irie K, Nakagawa A, Fujita H, et al. Pharmacokinetics of favipiravir in critically ill patients with COVID-19. Clin Transl Sci . 2020;13(5):880–885.
- D'Agostino RB. Jr. Propensity scores in cardiovascular research. Circulation. 2007;115(17):2340–2343.
- Bradburn MJ, Clark TG, Love SB, et al. Survival analysis part II: multivariate data analysis–an introduction to concepts and methods. Br J Cancer. 2003;89(3):431–436.